Beijing PLA General Hospital treats more than 1,000 neurosurgery patients
using VISIUS® Surgical Theatre
WINNIPEG, Nov. 15, 2012
iMRI assists in determining if all of tumor is removed
WINNIPEG, Nov. 15, 2012 /PRNewswire/ - IMRIS Inc. (NASDAQ: IMRS; TSX: IM)
("IMRIS" or the "Company") today announced PLA General Hospital in Beijing,
China, has surpassed a major milestone of treating more than 1,000
neurosurgery patients using a VISIUS^® Surgical Theatre. PLA General Hospital
was the first hospital in China to install a VISIUS Surgical Theatre featuring
a ceiling mounted, high-field intraoperative MR (iMRI) in February 2009.
"With the VISIUS Surgical Theatre, we recognized surgical precision
enhancement and the ability to improve the extent of resection and reduce
re-surgeries in tumor cases without moving the patient," said Dr. Bainian Xu,
hospital chief neurosurgeon. "Use of iMRI," he said, "provided us the three
M's of operation: maximum removal of lesion, minimum injury to neurologic
function, and marvelous patient recovery."
Dr. Xu added, "The percentage of patients with total resection (tumor removal)
in our department has been enhanced to 89%, and in 31% of all cases we
resected additional tumor after an intraoperative MR scan that would have
otherwise been missed." He also said this experience in improved precision is
leading to fast developing changes in operational theories and methods for
deep-brain, functional area and skull base procedures at their hospital.
The types of neurosurgical procedures included in the 1,000 cases are gliomas,
pituitary adenomas, vascular lesions, frameless biopsies, skull-based
procedures, metastatic tumor surgeries, epilepsy, and meningiomas.
This past April, Dr. Xiaolei Chen, associate professor of neurosurgery at PLA
General Hospital, presented preliminary results of the first randomized
clinical trial that studied the resection of low-grade insular glioma using
high-field 1.5T iMRI at the American Association of Neurological Surgeons
(AANS) annual meeting. The study results show significantly greater extent of
tumor resection, better rates of total resection and better long-term outcomes
for the group undergoing surgery with iMRI in a VISIUS Surgical Theatre,
compared to the control group without iMRI.
IMRIS (NASDAQ: IMRS; TSX: IM) is a global leader in providing image guided
therapy solutions through its VISIUS Surgical Theatre - a revolutionary,
multifunctional surgical environment that provides unmatched intraoperative
vision to clinicians to assist in decision making and enhance precision in
treatment. VISIUS Surgical Theatres serve the neurosurgical, cardiovascular
and cerebrovascular markets and have been selected by leading medical
institutions around the world.
SOURCE IMRIS Inc.
Director Investor Relations & Corporate Communications
Press spacebar to pause and continue. Press esc to stop.